Sam Altman-backed Startup Partners with Microsoft to Enable the AI Infrastructure for Drug Discovery

by Andrii Buvailo, PhD          News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or
Contributors are fully responsible for assuring they own any required copyright for any content they submit to This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   936    Comments 0
Topics: Emerging Technologies   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

A new five-year commercial agreement and go-to-market collaboration aims to merge 1910 Genetics' comprehensive computational and biological data with Microsoft’s HPC platform, Azure Quantum Elements. This union is expected to provide researchers worldwide access to a specialized cloud platform designed to expedite scientific discovery by leveraging the combined strengths of AI and HPC.

Founded in 2018 and based in Cambridge, Massachusetts, 1910 Genetics merges AI, computational analysis, and biological automation to expedite the creation of small-molecule and protein therapeutics. In 2021, the company raised a combined Seed and Series A funding of $26.1M backed by M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, and other leading investors.

By merging AI-driven drug design with wet lab automation, the company aims to enhance productivity, reduce failure rates in pharmaceutical R&D, and improve the efficiency of drug discovery processes. Leveraging its multi-platform engines, ELVIS™ and ROSALYND™, 1910 Genetics is capable of generating novel drug candidates more swiftly and cost-effectively, enhancing success probabilities compared to conventional pharmaceutical approaches. 

The company's technology is modality-agnostic and supports the entire early drug discovery process, from novel hit discovery through lead optimization. 1910 Genetics is actively applying its technology to various therapeutic areas, including neuroscience, infectious diseases, immunology, and oncology.

“We are thrilled to be collaborating with 1910 Genetics to bring their pioneering AI drug discovery engines to Azure Quantum Elements,” said Jason Zander, Executive Vice President of Strategic Missions and Technologies at Microsoft.


Building on the Lab Automation Trend

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *